About this trial
Periprosthetic joint infection (PJI) is a national health crisis and leads to very poor outcomes for patients undergoing elective joint replacement. Within the realm of elective total knee arthroplasty (TKA), various methods of infection prophylaxis are in place. These include sterile precautions, would/tissue handling, and antibiotic prophylaxis. With respect to the latter, various approaches have been utilized including intravenous and intraosseous administration of vancomycin, preoperatively. Intraosseous administration does require another wound and a specific device to administer. The investigators proposed that intraarticular injection of vancomycin is non-inferior to intraosseous administration, thus reducing wounds, time, and cost.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Any patient over the age of 18 years of age receiving treatment at UC San Diego Health
Undergoing primary unilateral TKA
Ability to provide consent
Disqualifiers
previous surgery on the knee (with the exception of arthroscopy)
BMI > 35
contraindication to receiving vancomycin, cefepime or cefazolin (ie, allergy, etc)
diabetics with A1c>7.5% (unless controlled fructosamine)
Trial design
Parallel
Treatments tested in this trial
Vancomycin
DrugIntraosseous or Intraarticular administration of Vancomycin
Treatment groups
Trial outcomes
Primary outcomes
Concentration of vancomycin in bone, synovial tissue, subcutaneous fat and serum blood
Sponsors and contacts
Click on the lead sponsor to view all of their trials.